Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

AlphaIIbbeta3 and its antagonism at the new millennium.

Plow EF, Cierniewski CS, Xiao Z, Haas TA, Byzova TV.

Thromb Haemost. 2001 Jul;86(1):34-40. Review.

PMID:
11487023
2.

Binding of [3H]-SK&F 107260 and [3H]-SB 214857 to purified integrin alphaIIbbeta3: evidence for a common binding site for cyclic arginyl-glycinyl-aspartic acid peptides and nonpeptides.

Wong A, Hwang SM, Johanson K, Samanen J, Bennett D, Landvatter SW, Chen W, Heys JR, Ali FE, Ku TW, Bondinell W, Nichols AJ, Powers DA, Stadel JM.

J Pharmacol Exp Ther. 1998 Apr;285(1):228-35.

3.

Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.

Peter K, Schwarz M, Ylänne J, Kohler B, Moser M, Nordt T, Salbach P, Kübler W, Bode C.

Blood. 1998 Nov 1;92(9):3240-9.

4.

Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Bledzka K, Smyth SS, Plow EF.

Circ Res. 2013 Apr 12;112(8):1189-200. doi: 10.1161/CIRCRESAHA.112.300570. Review.

5.
7.

GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.

Armstrong PC, Peter K.

Thromb Haemost. 2012 May;107(5):808-14. doi: 10.1160/TH11-10-0727. Review.

PMID:
22370973
8.

Peptide ligands can bind to distinct sites in integrin alphaIIbbeta3 and elicit different functional responses.

Cierniewski CS, Byzova T, Papierak M, Haas TA, Niewiarowska J, Zhang L, Cieslak M, Plow EF.

J Biol Chem. 1999 Jun 11;274(24):16923-32.

9.

The platelet integrin alphaIIbbeta3 binds to the RGD and AGD motifs in fibrinogen.

Sánchez-Cortés J, Mrksich M.

Chem Biol. 2009 Sep 25;16(9):990-1000. doi: 10.1016/j.chembiol.2009.08.012.

10.

A new model of dual interacting ligand binding sites on integrin alphaIIbbeta3.

Hu DD, White CA, Panzer-Knodle S, Page JD, Nicholson N, Smith JW.

J Biol Chem. 1999 Feb 19;274(8):4633-9.

11.

Integrin alphaIIbbeta3-specific synthetic human monoclonal antibodies and HCDR3 peptides that potently inhibit platelet aggregation.

Chung J, Rader C, Popkov M, Hur YM, Kim HK, Lee YJ, Barbas CF 3rd.

FASEB J. 2004 Feb;18(2):361-3.

PMID:
14688205
12.

A novel peptide motif for platelet fibrinogen receptor recognition.

Katada J, Hayashi Y, Sato Y, Muramatsu M, Takiguchi Y, Harada T, Fujiyoshi T, Uno I.

J Biol Chem. 1997 Mar 21;272(12):7720-6.

13.

[alphaIIbbeta3 modeling simulation and design of the cyclic RGD].

Luo M, Chen M, Lee I.

Sheng Wu Gong Cheng Xue Bao. 2008 Feb;24(2):297-301. Chinese.

PMID:
18464616
14.

Effect of synthetic peptides corresponding to residues 313-332 of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3.

Mitsios JV, Tambaki AP, Abatzis M, Biris N, Sakarellos-Daitsiotis M, Sakarellos C, Soteriadou K, Goudevenos J, Elisaf M, Tsoukatos D, Tsikaris V, Tselepis AD.

Eur J Biochem. 2004 Feb;271(4):855-62.

PMID:
14764102
15.
16.

Binding of a fibrinogen mimetic stabilizes integrin alphaIIbbeta3's open conformation.

Hantgan RR, Rocco M, Nagaswami C, Weisel JW.

Protein Sci. 2001 Aug;10(8):1614-26.

17.

αIIbβ3: structure and function.

Coller BS.

J Thromb Haemost. 2015 Jun;13 Suppl 1:S17-25. doi: 10.1111/jth.12915. Review.

18.

Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.

Bednar RA, Gaul SL, Hamill TG, Egbertson MS, Shafer JA, Hartman GD, Gould RJ, Bednar B.

J Pharmacol Exp Ther. 1998 Jun;285(3):1317-26.

19.
Items per page

Supplemental Content

Support Center